Stephen Jones STEPHEN JONES, US Oncology Research, Houston Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival adva
Stephen Jones
STEPHEN JONES, US Oncology Research, HoustonLong term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. AsStephen Jonesof US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.